Molecular Devices Corp.
This article was originally published in The Gray Sheet
Executive Summary
Secondary offering of $150 mil. in common stock is outlined in a filing with the Securities and Exchange Commission, including shares to be offered by the company and selling shareholders. Underwriters for the offering include ING Barings, Bear Stearns, Thomas Weisel Partners and Warburg Dillon Read. The Sunnyvale, California firm launched two high throughput microplate readers for use in drug discovery and life science research March 6, including the Spectramax Gemini XS fluorescence microplate reader and Plus384 absorbance microplate reader
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.